Logo

Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines

Share this

Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines

Shots:

  • This collaboration plans to use human genetics and machine learning to address unmet needs by developing precision medicines
  • Vertex will make £25M series B funding in Genomics (£10.5M equity investment) in addition to milestone and royalty payments from clinical developments to Genomics
  • Genomics with its largest unique analysis engine having 100B data points linking human genetic variation over 14M position in human genome to changes in 7k disease outcomes

            Ref: Vertex | Image:  Vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions